A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy Approaches

Weill Cornell Medicine (WCM) logo

Weill Cornell Medicine (WCM)

Status

Terminated

Conditions

Elevated PSA
Prostate Cancer

Treatments

Procedure: prostate biopsy

Study type

Interventional

Funder types

Other

Identifiers

NCT03632655
1705018187

Details and patient eligibility

About

This randomized trial will compare the safety and efficacy of TPM versus TRUS biopsies performed in the outpatient setting. Primary endpoints will be pain as well as detection of clinically significant disease (defined as Gleason Score >=7 or cancer core length >=6 mm). Secondary endpoints will be detection of any prostate cancer, hospital re-admissions within 30 days, aborted procedures due to discomfort, procedure time, adverse events including hematuria, urinary retention, hematospermia, hematochezia, and infection, and patient-reported outcomes as measured on validated instruments such as International Prostate Symptom Scores (IPSS) and International Index of Erectile Function (IIEF-5). In men who subsequently elect to undergo radical prostatectomy for definitive treatment of their prostate cancer, Gleason scores at final pathology will be correlated to the Gleason scores obtained at time of biopsy.

Full description

The feasibility of outpatient TPM has been well demonstrated.(Bianco & Martínez-Salamanca, 2016; Merrick et al., 2016; Smith et al., 2014) New technology now allows for fusion of MRI images with TPM devices, allowing for targeting of cancerous-appearing lesions on MRI. Such technology that fuses MRI-imaging with TRUS biopsy has become routine in U.S. clinical practice, with improved cancer detection rates as compared with standard TRUS.(Ahmed et al., 2017; Robertson, Emberton, & Moore, 2013) This randomized trial will compare the safety and efficacy of TPM versus TRUS biopsies performed in the outpatient setting. Men will be randomized to receiving either TPM or TRUS targeted biopsy. All men will receive a urine culture within 2 weeks of biopsy and will be started on antibiotic prophylaxis prior to biopsy in accordance with AUA antimicrobial prophylaxis guidelines. Men with a positive urine culture will be treated with culture-specific antibiotics and must have a documented negative urine culture prior to biopsy.

Enrollment

38 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men 18 years or older with suspicion for prostate cancer based upon an elevated PSA, abnormal digital rectal examination, abnormal MRI
  • Men on active surveillance with indication for biopsy

Exclusion criteria

  • Men with active urinary tract infection, metastatic prostate cancer, history of colorectal surgery limiting insertion of transrectal probe, evidence of acute or chronic prostatitis, or concern for perineal cellulitis or fistula
  • Men unfit to undergo prostate biopsy under local anesthesia
  • Men with prior definitive therapy for prostate cancer, such as radiation therapy or partial gland ablation
  • Men with contraindication to prostate MRI (claustrophobia, pacemaker, chronic kidney disease)

Trial design

Primary purpose

Diagnostic

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

38 participants in 2 patient groups

Transrectal Ultrasound Guided Biopsy (TRUS)
Active Comparator group
Description:
Patients will receive a transrectal guided prostate biopsy
Treatment:
Procedure: prostate biopsy
Transperineal Prostate Biopsy
Active Comparator group
Description:
Patients will receive a transperineal prostate biopsy
Treatment:
Procedure: prostate biopsy

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems